Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2105 of 6351
-
Can a booster shot for the immune system prevent more infections in sepsis survivors?
Disease control CompletedThe concept of acquired immunodeficiency after a first severe infection in the ICU is widely described in the literature. There is a dual risk: increased mortality and increased secondary infections. Several approaches of immunostimulatory treatments have been proposed in the lit…
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Brain implant gives voice to the locked-in
Knowledge-focused CompletedIn this study a new means of communication for people with locked-in syndrome will be tested. The investigators will record brain signals directly from the surface of the brain by means of a completely implantable system. These brain signals are fed wirelessly into an assistive t…
Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Blood pressure drugs may slow brain damage in seniors
Disease control Recruiting nowThe purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
New drug combo shows promise in head and neck cancer trial
Disease control CompletedThe phase I trial aims to determine the recommended phase II dose (RP2D) and schedule of olaparib in combination with standard cisplatin-based chemoradiotherapy, in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (HNSCC), by assessing the saf…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Engineered immune cells take on HPV cancers in early trial
Disease control CompletedSubjects have a type of cancer that has been associated with an infection with a virus called human papilloma virus (HPV). The cancer has come back, has not gone away after standard treatment or the subject cannot receive standard treatment. This is a research study using specia…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Light exercise may speed concussion recovery in teens
Symptom relief CompletedAdolescents with concussion will be randomly assigned to a treatment group where they will receive sub-threshold exercise, or assigned to a placebo group where they will receive structured stretching exercises. Both groups will receive standard medical coverage with regular clini…
Sponsor: University at Buffalo • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Spinal stimulation device aims to restore bladder control in paralyzed patients
Symptom relief Recruiting nowThis trial will investigate the safety and utility of spinal cord neuromodulation to improve urinary bladder function in the context of spinal cord injury.
Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Scientists reprogram leukemia cells to fight themselves
Disease control OngoingThis is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow …
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
One-Shot hybrid procedure takes on stubborn atrial fibrillation
Disease control CompletedThe objective of the study is to investigate the feasibility of a hybrid procedure removal of the atrial fibrillation. This is a single procedure for both surgical epicardial by minimally invasive route (Thoracoscopy) without even flow controlled and supplemented if necessary by…
Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Kids' cancer genes mapped in massive study
Knowledge-focused Recruiting nowThe development of next generation sequencing (NGS) techniques, including whole genome (WGS), exome (WES) and RNA sequencing has revolutionized the ability of investigators to query the molecular mechanisms underlying tumor formation. Through the Pediatric Cancer Genome Project (…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control OngoingThis phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer respo…
Phase 1/2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Targeted drug trametinib tested on rare BRAF cancers
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trametinib may block proteins called MEK1 and MEK2, which may be needed for growth of cancer cells that express BRAF mutation…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug shows promise for rare HER2-Positive cancers
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification. Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trast…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted drug afatinib tested against HER2-Mutated tumors
Disease control OngoingThis phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations. Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Researchers hope to…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New stent graft offers hope for aortic tear patients
Disease control CompletedAssess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® Ascending Stent Graft
Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Promising new cocktail aims to tame multiple myeloma with fewer side effects
Disease control CompletedThe goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
Phase 2 • Sponsor: John L. Reagan • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can big data improve shoulder replacement success?
Knowledge-focused Recruiting nowThe objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Sponsor: Arthrex, Inc. • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Precision radiation for prostate cancer shows promise in early trial
Disease control CompletedThis phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with prostate cancer. Stereotactic body radiation therapy is …
Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 26, 2026 14:15 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread from where it first started (primary site) to other places in t…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC